Effect of Inhaled Tacrolimus on Cellular and Humoral Rejection to Prevent Posttransplant Obliterative Airway Disease
Schrepfer S, Deuse T, Reichenspurner H, Hoffmann J, Haddad M, Fink J, Fischbein M, Robbins R, Pelletier M. Effect of Inhaled Tacrolimus on Cellular and Humoral Rejection to Prevent Posttransplant Obliterative Airway Disease. American Journal Of Transplantation 2007, 7: 1733-1742. PMID: 17532751, DOI: 10.1111/j.1600-6143.2007.01858.x.Peer-Reviewed Original ResearchConceptsObliterative airway diseaseTreatment groupsAirway diseaseSystemic side effectsCellular immune activationOrthotopic tracheal transplantationGraft infiltrationCellular rejectionCellular immunosuppressionHumoral rejectionAllograft rejectionElevated BUNImmune activationTacrolimusAerosol inhalationMononuclear infiltrationSide effectsPOD 8Tracheal transplantationAirway graftsPO animalsHistology of graftsGraftTreatmentPodsIs the Malononitrilamide FK778 Better for the Prevention of Acute or Chronic Rejection?
Deuse T, Schrepfer S, Pelletier M, Fischbein M, Robbins R, Reichenspurner H. Is the Malononitrilamide FK778 Better for the Prevention of Acute or Chronic Rejection? Transplantation Proceedings 2007, 39: 569-572. PMID: 17362784, DOI: 10.1016/j.transproceed.2006.12.020.Peer-Reviewed Original ResearchConceptsObliterative airway diseaseUntreated recipientsLuminal obliterationComplete luminal obliterationEfficacy of FK778Rat cardiac transplantsTracheal luminal obliterationCardiac allograft survivalProlonged graft survivalChronic allograft rejectionAcute heart rejectionMalononitrilamide FK778Mycophenolate mofetilAllograft survivalChronic rejectionCardiac transplantationImmunosuppressive agentsAllograft rejectionGraft survivalFK778Heart rejectionAirway diseaseTacrolimusTracheal transplantationIntense infiltrationTechniques for experimental heterotopic and orthotopic tracheal transplantations — When to use which model?
Deuse T, Schrepfer S, Reichenspurner H, Hoyt G, Fischbein M, Robbins R, Pelletier M. Techniques for experimental heterotopic and orthotopic tracheal transplantations — When to use which model? Transplant Immunology 2007, 17: 255-261. PMID: 17493528, DOI: 10.1016/j.trim.2007.01.009.Peer-Reviewed Original ResearchConceptsObliterative airway diseaseOrthotopic tracheal transplantationTracheal transplantationOrthotopic tracheal transplantation modelIFN-gamma ELISPOT assayHuman lung transplant recipientsSystemic host immune responseIFN-gamma ELISPOTTracheal transplant modelDays post-transplantLung transplant recipientsSyngeneic tracheal graftsHost immune responseBrown Norway-to-LewisCellular host responseIgM antibody productionTransplant recipientsPost-transplantAirway epitheliumLuminal obliterationTransplantation modelLuminal occlusionHeterotopic allograftsAirway diseaseHumoral responseExperimental orthotopic tracheal transplantation: The stanford technique
Schrepfer S, Deuse T, Hoyt G, Sheikh A, Hoffmann J, Reichenspurner H, Robbins R, Pelletier M. Experimental orthotopic tracheal transplantation: The stanford technique. Microsurgery 2007, 27: 187-189. PMID: 17326196, DOI: 10.1002/micr.20329.Peer-Reviewed Original ResearchConceptsObliterative airway diseaseTransplantation modelDevelopment of obliterative airway diseaseHeterotopic tracheal transplant modelRat heterotopic tracheal transplant modelTracheal transplant modelOAD lesionsHeterotopic transplantation modelOrthotopic tracheal transplantationImmunosuppressive strategiesChronic rejectionObliterative bronchiolitisLung transplantationSurgical techniqueAirway diseaseMucociliary clearanceTracheal transplantation
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply